Statera BioPharma Gross Profit

The latest gross profit for STAB is $2.6M as of September 2022. That compares with $120K in the prior-year period — up 2048.8% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside Statera BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, STAB's gross profit moved from $120K to $2.6M — a 2048.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Statera BioPharma's operating scale or balance-sheet position.

Against Healthcare companies, STAB currently prints $2.6M for gross profit, while the sector average sits near $66B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Statera BioPharma's growth, margins, and balance sheet.

A gross profit figure of $2.6M for STAB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting STAB's gross profit ($2.6M), review year-over-year change from $120K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.